A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-01. Anything still debated is marked as such rather than presented as settled.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Water is the main source of hydrogen for all living things, so the isotopic composition of environmental water is a first-order control on that of the biosphere. The water (hydrological) cycle moves water around Earth's surface, significantly fractionating the hydrogen isotopes in water. As the atmosphere's main moisture source, the ocean has a fairly uniform HIC across the globe around 0‰ (VSMOW). Variations of δD larger than 10‰ in the ocean are generally confined to surface water due to evaporation, sea ice formation, and addition of meteoric water by precipitation, rivers or icebergs. In the water cycle, the two main processes that fractionate hydrogen isotopes from seawater are evaporation and condensation. Oxygen isotopic composition (18O/16O) of water is also an important tracer in the water cycle, and cannot be separated from hydrogen isotopes when we talk about isotope fractionation processes associated with water. When water evaporates from the ocean to the air, both equilibrium and kinetic isotope effects occur to determine the hydrogen and oxygen isotopic composition of the resulting water vapor. At the water-air interface, a stagnant boundary layer is saturated with water vapor (100% relative humidity), and the isotopic composition of water vapor in the boundary layer reflects an equilibrium fractionation with liquid water. The liquid-vapor equilibrium fractionations for hydrogen and oxygen isotopes are temperature-dependent:
Gastric acid production is regulated by both the autonomic nervous system and several hormones. The parasympathetic nervous system, via the vagus nerve, and the hormone gastrin stimulate the parietal cell to produce gastric acid, both directly acting on parietal cells and indirectly, through the stimulation of the secretion of the hormone histamine from enterochromaffin-like cells (ECLs). Vasoactive intestinal peptide, cholecystokinin, and secretin all inhibit production. The production of gastric acid in the stomach is tightly regulated by positive regulators and negative feedback mechanisms. Four types of cells are involved in this process: parietal cells, G cells, D cells and enterochromaffin-like cells. Beside this, the endings of the vagus nerve (CN X) and the intramural nervous plexus in the digestive tract influence the secretion significantly. Nerve endings in the stomach secrete two stimulatory neurotransmitters: acetylcholine and gastrin-releasing peptide. Their action is both direct on parietal cells and mediated through the secretion of gastrin from G cells and histamine from enterochromaffin-like cells. Gastrin acts on parietal cells directly and indirectly too, by stimulating the release of histamine. The release of histamine is the most important positive regulation mechanism of the secretion of gastric acid in the stomach. Its release is stimulated by gastrin and acetylcholine and inhibited by somatostatin.
In what became known as "The Six Boers Case", Captains Robertson and Taylor, as well as Sgt. Maj. Morrison, were charged with committing the offense of murder while on active service. In relation to what was dubbed "The Van Buuren Incident", Maj. Lenahan was charged with, "When on active service by culpable neglect failing to make a report which it was his duty to make." In relation to "The Visser Incident", Lts. Morant, Handcock, Witton, and Picton were charged with "While on active service committing the offense of murder". In relation to what was incorrectly dubbed "The Eight Boers Case", Lieuts. Morant, Handcock, and Witton were charged with, "While on active service committing the offense of murder". In relation to the slaying of Heese, Lts. Morant and Handcock were charged with, "While on active service committing the offense of murder". No charges were filed for the three children who had been shot by the Bushveldt Carbineers near Fort Edward. In relation to what became known as "The Three Boers Case", Lts. Morant and Handcock were charged with, "While on active service committing the offense of murder". Following the indictments, Maj. R. Whigham and Col. James St. Clair ordered Bolton to appear for the prosecution, as he was less expensive than a barrister. Bolton vainly requested to be excused, writing, "My knowledge of law is insufficient for so intricate a matter." The first court martial opened on 16 January 1902, with Lieut.-Col. H.C. Denny presiding over a panel of six judges. Maj. J.F.
== External links == Intrinsically disordered protein at Proteopedia MobiDB: a comprehensive database of intrinsic protein disorder annotations IDEAL - Intrinsically Disordered proteins with Extensive Annotations and Literature Archived 2020-05-02 at the Wayback Machine D2P2 Database of Disordered Protein Predictions Gallery of images of intrinsically disordered proteins First IDP journal covering all topics of IDP research IDP Journal Database of experimentally validated IDPs IDP ensemble database Archived 2018-03-10 at the Wayback Machine
Sources: en.wikipedia.org
=== 1999 === 3 January Apocalypse, When?, an Equinox Special, the title originates from the 1979 film Apocalypse Now; at Garland, Texas the Chen Tao (UFO religion) believed that God would broadcast to Earth on Channel 18 at midnight on 24 March 1998; the journalist Damian Thompson, who wrote on apocalyptic beliefs; historian Richard Landes; historian Kristen Lippincott, and how the Egyptians invented the solar calendar of 365 days around four thousand years ago; computer scientist Nachum Dershowitz; journalist Marina Benjamin and the Book of Revelation; in 45 BC, the Romans introduced the calendar as we largely know today, with leap years and twelve months, with July and August having 31 days; Constantine the Great became a Christian in 312, so formed the seven-day week in 321; AD years were started by Dionysius Exiguus in 525, and the date of Easter; the forthcoming rapture; Father Michael Evans of Belmont Abbey, Herefordshire; Gwynneth Flower of Action 2000, and Peter de Jager.
== Class D peptidomimetics == These mechanistic mimetics do not directly recapitulate the side chains or conformation of a peptide but mimic its mode-of-action. Class D peptidomimetics can be directly designed from a small peptide sequence or identified the screening of compound libraries. For example, Nirmatrelvir is an orally-active small molecule drug derived from lufotrelvir, a modified L-peptide.
=== Kidneys === The renal parenchyma is divided into two major structures: the outer renal cortex and the inner renal medulla. Grossly, these structures take the shape of 7 to 18 cone-shaped renal lobes, each containing renal cortex surrounding a portion of medulla called a renal pyramid.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.